Document is current
Any future updates will be listed below
-
Authors
Loomis, Stephanie J.
Sadhu, Nilanjana
Fisher, Elizabeth
Gafson, Arie R.
Huang, Yunfeng
Yang, Chengran
Hughes, Emily E.
Marshall, Eric
Herman, Ann
John, Sally
Runz, Heiko
Jia, Xiaoming
Bhangale, Tushar
Bronson, Paola G.
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct01416181 at ClinicalTrials.govnct00906399 at ClinicalTrials.govDocuments that mention this clinical trial
Chronic lesion activity and disability progression in secondary progressive multiple sclerosis
https://doi.org/10.1136/bmjno-2021-000240
Disease modification in multiple sclerosis: an update
https://doi.org/10.1136/practneurol-2013-000601
Genome-wide study of longitudinal brain imaging measures of multiple sclerosis progression across six clinical trials
https://doi.org/10.1038/s41598-023-41099-0
Comorbidities, safety and persistence in phase III clinical trials in multiple sclerosis
https://doi.org/10.1136/jnnp-2024-335710
nct01064401 at ClinicalTrials.govDocuments that mention this clinical trial
Disease modification in multiple sclerosis: an update
https://doi.org/10.1136/practneurol-2013-000601
Genome-wide study of longitudinal brain imaging measures of multiple sclerosis progression across six clinical trials
https://doi.org/10.1038/s41598-023-41099-0
Comorbidities, safety and persistence in phase III clinical trials in multiple sclerosis
https://doi.org/10.1136/jnnp-2024-335710
nct01247324 at ClinicalTrials.govDocuments that mention this clinical trial
Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial
https://doi.org/10.1016/s0140-6736(12)62190-4
Genome-wide study of longitudinal brain imaging measures of multiple sclerosis progression across six clinical trials
https://doi.org/10.1038/s41598-023-41099-0
nct01412333 at ClinicalTrials.govDocuments that mention this clinical trial
060 Association of brain volume loss and neda outcomes in patients with relapsing multiple sclerosis in the opera i and opera ii studies (ENCORE)
https://doi.org/10.1136/jnnp-2018-anzan.59
PO128 Infusion-related reactions with ocrelizumab in rms and ppms
https://doi.org/10.1136/jnnp-2017-abn.158
177 Updated safety analysis of ocrelizumab in multiple sclerosis
https://doi.org/10.1136/jnnp-2019-abn-2.157
178 Long-term efficacy of ocrelizumab in relapsing multiple sclerosis
https://doi.org/10.1136/jnnp-2019-abn-2.158
020 Long-term efficacy of ocrelizumab in relapsing multiple sclerosis: 6 study years
https://doi.org/10.1136/jnnp-2022-abn.59
Genome-wide study of longitudinal brain imaging measures of multiple sclerosis progression across six clinical trials
https://doi.org/10.1038/s41598-023-41099-0
034 Updated safety analysis of ocrelizumab in multiple sclerosis
https://doi.org/10.1136/jnnp-2022-abn.73
Comorbidities, safety and persistence in phase III clinical trials in multiple sclerosis
https://doi.org/10.1136/jnnp-2024-335710
WED 187 Infections in ocrelizumab recipients from phase III studies
https://doi.org/10.1136/jnnp-2018-abn.92
THUR 179 Ocrelizumab effect on neda in patient subgroups of opera I and opera II
https://doi.org/10.1136/jnnp-2018-abn.84
PO129 Neda analysis by epoch in the opera studies of ocrelizumab
https://doi.org/10.1136/jnnp-2017-abn.159
033 Ocrelizumab: serum Ig levels and serious infections
https://doi.org/10.1136/jnnp-2022-abn.72
OCRELIZUMAB VS INTERFERON β-1A IN RELAPSING MS: TWO STUDIES
https://doi.org/10.1136/jnnp-2016-315106.144
061 Ocrelizumab reduces disability progression independent of relapse activity in patients with relapsing multiple sclerosis (RMS) (ENCORE)
https://doi.org/10.1136/jnnp-2018-anzan.60
nct01194570 at ClinicalTrials.govDocuments that mention this clinical trial
177 Updated safety analysis of ocrelizumab in multiple sclerosis
https://doi.org/10.1136/jnnp-2019-abn-2.157
Genome-wide study of longitudinal brain imaging measures of multiple sclerosis progression across six clinical trials
https://doi.org/10.1038/s41598-023-41099-0
Comorbidities, safety and persistence in phase III clinical trials in multiple sclerosis
https://doi.org/10.1136/jnnp-2024-335710
OCRELIZUMAB VS INTERFERON β-1A IN RELAPSING MS: TWO STUDIES
https://doi.org/10.1136/jnnp-2016-315106.144
Documents that mention this clinical trial
PO128 Infusion-related reactions with ocrelizumab in rms and ppms
https://doi.org/10.1136/jnnp-2017-abn.158
177 Updated safety analysis of ocrelizumab in multiple sclerosis
https://doi.org/10.1136/jnnp-2019-abn-2.157
Evolution of atrophied T2 lesion volume in primary-progressive multiple sclerosis: results from the phase 3 ORATORIO study
https://doi.org/10.1136/jnnp-2023-332573
PO127 Composite confirmed disability progression in oratorio
https://doi.org/10.1136/jnnp-2017-abn.157
Genome-wide study of longitudinal brain imaging measures of multiple sclerosis progression across six clinical trials
https://doi.org/10.1038/s41598-023-41099-0
034 Updated safety analysis of ocrelizumab in multiple sclerosis
https://doi.org/10.1136/jnnp-2022-abn.73
Comorbidities, safety and persistence in phase III clinical trials in multiple sclerosis
https://doi.org/10.1136/jnnp-2024-335710
031 Long-term efficacy of ocrelizumab in primary progressive multiple sclerosis: 6.5-study years
https://doi.org/10.1136/jnnp-2022-abn.70
WED 187 Infections in ocrelizumab recipients from phase III studies
https://doi.org/10.1136/jnnp-2018-abn.92
033 Ocrelizumab: serum Ig levels and serious infections
https://doi.org/10.1136/jnnp-2022-abn.72
OCRELIZUMAB IN PRIMARY PROGRESSIVE MS: THE ORATORIO STUDY
https://doi.org/10.1136/jnnp-2016-315106.143
- License Information
-
More Information
Article History
Received: 7 March 2023
Accepted: 22 August 2023
First Online: 31 August 2023
Competing interests
: SJL, NS, CY, EH, EF, EM, AG, HR, SJ, PGB are/were employees of Biogen and may hold stocks/stock options in Biogen. AH, XJ and TB are employees of Genentech (a subsidiary of Roche) and may hold stocks/stock options in F. Hoffmann-La Roche Ltd.
